The Analyst Verdict: MaxLinear In The Eyes Of 10 Experts
Portfolio Pulse from Benzinga Insights
MaxLinear (NASDAQ:MXL) has been evaluated by 10 analysts over the last three months, with a mix of bullish to bearish sentiments. The average 12-month price target for MXL is now $26.5, down from the previous $36.11, indicating a 26.61% decline. Several analysts from firms like Wells Fargo, Stifel, Benchmark, Susquehanna, Roth MKM, and Deutsche Bank have lowered their price targets for MXL. MaxLinear faces revenue challenges with a -52.57% decline over 3 months and has a net margin of -29.39%, but a relatively healthy debt-to-equity ratio of 0.23.
January 03, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
MaxLinear's average 12-month price target has been lowered to $26.5, indicating a negative sentiment among analysts. The company's revenue has declined significantly, and its net margin is below industry averages, although it has a good debt-to-equity ratio.
The lowered price targets and the negative revenue growth suggest a bearish outlook for MaxLinear in the short term. The consistent lowering of price targets by multiple analysts reflects a consensus that could influence investor sentiment and stock price negatively. However, the company's debt management may provide some support to the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100